REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis

Clinical trial NCT06315010 · RECRUITING

Trial details

NCT number: NCT06315010
Sponsor: MedSIR
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

NSCLC Brain Metastases ROS1 Gene Rearrangement

Start date: 2025-06-27
Primary completion: 2027-03-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.